Alexandre Merieux - BioMrieux CEO, Director and Member of Strategy Committee
| BMXMF Stock | USD 105.00 1.83 1.77% |
CEO
Mr. Alexandre Merieux has served as Chairman of the Board, Chairman of the Executive Committee, Chief Executive Officer, NonIndependent Director since December 15, 2017. He was prior Chief Operating Officer from January 1, 2017 to December 15, 2017. Mr. Alexandre Merieux was Chief Executive Officer, Member of the Management Committee and Director at Biomerieux SA. He previously worked for the Company as Deputy Chief Executive Officer, Corporationrationrate Vice President Industrial Microbiology, Member of the Management Committee and Director from December 19, 2008 to March 31, 2011. Prior to that, he was the Company Corporationrationrate Vice President Industrial Microbiology, Member of the Management Committee and Director until December 19, 2008. He was first appointed to the Company Board of Directors on April 16, 2004. From 1999 to 2004, Mr. Merieux served at the Silliker Group Corporationrationration, working in marketing in the United States and Europe and as Marketing and Business Unit director in France. He joined the Industrial Microbiology division of BioMerieux Inc in 2005. Mr. Merieux holds a degree in Biology from Universite Claude Bernard Lyon I and is a graduate of HEC Montreal Business School . He currently also holds several other posts, including Chairman of SGH, Director of Fondation Christophe et Rodolphe Merieux and Director of bioMerieux China Ltd., among others. since 2017.
| Age | 49 |
| Tenure | 7 years |
| Phone | 33 4 78 87 20 00 |
| Web | https://www.biomerieux.com |
BioMrieux Management Efficiency
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. BioMrieux's management efficiency ratios could be used to measure how well BioMrieux manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CEO Age | ||
| Christopher Thatcher | Neuronetics | 53 | |
| Scott Hutton | BiodesixInc | 52 | |
| Keith Sullivan | Neuronetics | 66 | |
| Ilan Danieli | Precipio | 52 | |
| Chris Thatcher | Neuronetics | N/A | |
| Harry Simeonidis | Intelligent Bio Solutions | 57 | |
| Timothy Damadian | Fonar | 60 | |
Management Performance
bioMrieux SA Leadership Team
Elected by the shareholders, the BioMrieux's board of directors comprises two types of representatives: BioMrieux inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMrieux. The board's role is to monitor BioMrieux's management team and ensure that shareholders' interests are well served. BioMrieux's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMrieux's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guillaume Bouhours, Corporate Vice President CFO, Member of the Executive Board | ||
| Fanny Letier, Independent Director | ||
| Frederic Beseme, Head CSR | ||
| Philippe Archinard, Director | ||
| Francois Lacoste, Member of the Management Committee, Director of Immunoassay Unit | ||
| Wei Ding, Member of the Management Committee, CEO of bioTheranostics | ||
| Alexandre Merieux, CEO, Director and Member of Strategy Committee | ||
| Kirk Ririe, Chief Innovation Officer | ||
| Alain Pluquet, CTO and Corporate VP of Innovation | ||
| Stefan Willemsen, Group Chief Legal Officer and Corporate VP of America Region | ||
| Claire Giraut, Member of the Management Committee and Corporate Vice President and CFO, Administrative Director | ||
| Harold Boel, Independent Director | ||
| Sylvain Morgeau, Head of Investor Relations | ||
| Pierre Boulud, Corporate Vice-President Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning | ||
| Michel Baguenault, Member of the Management Committee, Director of Human Resources and Communication | ||
| Nicolas Cartier, Member of the Management Committee, Director of Industrial Microbiology Unit | ||
| MariePaule Kieny, Independent Director | ||
| Isabelle Tongio, Investor Relations Manager | ||
| Yasha Mitrotti, Corporate Vice President Europe, Middle East, Africa Region, Member of the Management Committee | ||
| Agnes Lemarchand, Independent Director | ||
| JeanLuc Belingard, Chairman of the Board | ||
| Philippe Gillet, Independent Director | ||
| Michele Palladino, Independent Director | ||
| Mark Miller, Member of the Management Committee, Chief Medical Officer and Head of Regulatory Affairs | ||
| Valerie Leylde, Communications HR | ||
| Pierre Charbonnier, Corporate Vice President Manufacturing & Supply Chain, Member of the Management Committee | ||
| Alain Merieux, Director | ||
| MarieHelene HabertDassault, Independent Director | ||
| Randy Rasmussen, Corporate Vice President Molecular Biology, Member of the Management Committee | ||
| Franois Lacoste, Ex RD |
BioMrieux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioMrieux a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.99 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.40 % | |||
| Price To Earning | 23.91 X | |||
| Price To Book | 3.18 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioMrieux in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioMrieux's short interest history, or implied volatility extrapolated from BioMrieux options trading.
Pair Trading with BioMrieux
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioMrieux position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioMrieux will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to BioMrieux could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioMrieux when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioMrieux - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling bioMrieux SA to buy it.
The correlation of BioMrieux is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioMrieux moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if bioMrieux SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioMrieux can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioMrieux SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for BioMrieux Pink Sheet analysis
When running BioMrieux's price analysis, check to measure BioMrieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMrieux is operating at the current time. Most of BioMrieux's value examination focuses on studying past and present price action to predict the probability of BioMrieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMrieux's price. Additionally, you may evaluate how the addition of BioMrieux to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |